OTCMKTS:HLTRF HLS Therapeutics (HLTRF) Stock Price, News & Analysis → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free HLTRF Stock Alerts $2.90 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.90▼$2.9050-Day Range$2.75▼$4.0052-Week Range$2.60▼$4.95VolumeN/AAverage Volume1,100 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$20.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get HLS Therapeutics alerts: Email Address Ad InvestorPlaceWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details About HLS Therapeutics Stock (OTCMKTS:HLTRF)HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Read More HLTRF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLTRF Stock News HeadlinesMay 9, 2024 | finance.yahoo.comAn Intrinsic Calculation For HLS Therapeutics Inc. (TSE:HLS) Suggests It's 44% UndervaluedApril 25, 2024 | finance.yahoo.comHLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference CallFebruary 29, 2024 | finance.yahoo.comHLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference CallFebruary 6, 2024 | morningstar.comHLS Therapeutics IncDecember 5, 2023 | finance.yahoo.comHLS Therapeutics (TSE:HLS) shareholders have endured a 78% loss from investing in the stock three years agoOctober 26, 2023 | finance.yahoo.comHLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference CallSeptember 6, 2023 | finance.yahoo.comHLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment ConferenceAugust 10, 2023 | finance.yahoo.comHLS Therapeutics Announces Q2 Fiscal 2023 Financial ResultsJune 8, 2023 | marketwatch.comHLS Therapeutics Chairman to Retire; Polar Nominee to Join BoardMay 12, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Receives a Buy from ClarusMay 3, 2023 | finance.yahoo.comHLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference CallApril 21, 2023 | finance.yahoo.comHLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 17, 2023 | marketwatch.comHLS Therapeutics Appoints Craig Millian CEO to Head CompanyMarch 15, 2023 | markets.businessinsider.comHLS Therapeutics earnings: here's what Wall Street expectsMarch 2, 2023 | finance.yahoo.comHLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference CallJanuary 12, 2023 | finance.yahoo.comShareholders in HLS Therapeutics (TSE:HLS) are in the red if they invested three years agoJanuary 1, 2023 | finance.yahoo.comHLS Therapeutics Inc. (HLTRF)December 14, 2022 | finance.yahoo.comHLS Therapeutics Inc. (TSE:HLS): When Will It Breakeven?November 10, 2022 | finance.yahoo.comHLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer BidOctober 5, 2022 | benzinga.comHLS Therapeutics Stock (OTC:HLTRF), Guidance and ForecastOctober 3, 2022 | finance.yahoo.comHLS Therapeutics Announces Updates to its Credit AgreementApril 28, 2022 | finance.yahoo.comHLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference CallApril 26, 2022 | marketwatch.comHLS Therapeutics Completes Letter of Intent With Canada Alliance on VascepaApril 26, 2022 | finance.yahoo.comHLS Therapeutics completes negotiations with pCPA for Vascepa®March 14, 2022 | finance.yahoo.comHLS Therapeutics to Host Q4 & Fiscal 2021 Financial Results Conference CallSee More Headlines Receive HLTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HLTRF CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees91Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$36.00 Low Stock Price Target$5.00 Potential Upside/Downside+606.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Craig Stuart Millian M.B.A. (Age 56)CEO & Director Comp: $700.33kMr. John Hanna C.P.A. (Age 59)CGA, M.B.A., Interim CFO & Non-Independent Director Comp: $31.48kDr. Jason A. Gross Pharm.D. (Age 59)Vice President of Scientific Affairs Comp: $269.02kMr. Ryan C. Lennox B.A. (Age 43)J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary Comp: $322.83kMr. Brian T. WalshSenior Vice President of CommercialMr. David Spence (Age 56)VP & Corporate Controller More ExecutivesKey CompetitorsChina Infrastructure ConstructionOTCMKTS:CHNCDecibel CannabisOTCMKTS:DBCCFHempOTCMKTS:HEMPInvictus MD StrategiesOTCMKTS:IVITFMedMen EnterprisesOTCMKTS:MMNFFView All Competitors HLTRF Stock Analysis - Frequently Asked Questions Should I buy or sell HLS Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares. View HLTRF analyst ratings or view top-rated stocks. What is HLS Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 1-year price objectives for HLS Therapeutics' stock. Their HLTRF share price targets range from $5.00 to $36.00. On average, they expect the company's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 606.9% from the stock's current price. View analysts price targets for HLTRF or view top-rated stocks among Wall Street analysts. How have HLTRF shares performed in 2024? HLS Therapeutics' stock was trading at $3.84 at the beginning of the year. Since then, HLTRF shares have decreased by 24.5% and is now trading at $2.90. View the best growth stocks for 2024 here. Are investors shorting HLS Therapeutics? HLS Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 3,400 shares, a drop of 8.1% from the April 30th total of 3,700 shares. Based on an average daily trading volume, of 1,100 shares, the days-to-cover ratio is presently 3.1 days. View HLS Therapeutics' Short Interest. How do I buy shares of HLS Therapeutics? Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HLTRF) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBill Clinton Backing Biden Replacement???The Freeport SocietyDems have chosen Biden replacement?Paradigm PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaElon’s New A.I. Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.